地西他滨联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤的疗效分析

Analysis of the efficacy of decitabine combined with bortezomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma

目的观察地西他滨联合硼替佐米和地塞米松(VD)化疗方案在复发或难治性多发性骨髓瘤患者中的疗效和不良反应。方法回顾性分析2017年1月至2019年12月于河南省肿瘤医院血液科收治的28例应用地西他滨联合VD方案治疗的复发或难治性多发性骨髓瘤患者的安全性、缓解率以及无进展生存期(PFS)。结果中位随访时间为8.22(2.00~32.90)个月。总体缓解率为21.43%,其中4例(14.29%)获得完全缓解,2例(7.14%)获得非常好的部分缓解。最常见的不良反应是血小板降低(85.71%)、贫血(78.57%)、中性粒细胞减少(64.29%)和恶心(64.29%)。经过积极的治疗后,大部分不良反应可得到有效的控制和恢复。结论对于多次复发的多发性骨髓瘤患者,地西他滨联合VD方案尚不能作为一种有效的治疗手段。

Objective To investigate the effect and adverse reactions of decitabine combined with VD(bortezomib and dexamethasone)chemotherapy in patients with relapsed or refractory multiple myeloma.Methods A total of 28 patients with relapsed/refractory multiple myeloma diagnosed in the Hematology Department of Henan Provincial Tumor Hospital from January 2017 to December 2019 were selected as the research subjects.The safety remission rate and progression-free survival were retrospectively analyzed.Results The median follow-up time was 8.22(2.00-32.90)months with the overall remission rate of 21.43%.Among them,there were 4 cases(14.29%)with complete remission and 2 case(7.14%)with very good partial remission.The most common adverse reactions were thrombocytopenia(85.71%),anemia(78.57%),neutropenia(64.29%)and nausea(64.29%).After active treatment,most adverse reactions could to be effectively controlled and recovered.Conclusion For patients with recurrent multiple myeloma,decitabine combined with VD chemotherapy can not be used as a treatment.